Literature DB >> 22273575

Immunohistochemical characterization of nonhuman primate ovarian sex cord-stromal tumors.

A Durkes1, M Garner, C Juan-Sallés, J Ramos-Vara.   

Abstract

This study evaluates the immunoreactivity of 12 sex cord-stromal tumors of nonhuman primates (11 granulosa cell tumors and 1 luteoma). The markers selected are used in the characterization of gonadal tumors in dogs and other species, including cytokeratins AE1/AE3, GATA-4, inhibin-α, neuron-specific enolase, protein gene product 9.5, and vimentin. A normal nonhuman primate ovary was used as a control and to optimize immunolabeling. Staining was graded as follows: 0 (nonstaining), 1+ (< 10% positive cells), 2+ (10%-50% positive cells), and 3+ (> 50% positive cells). Calretinin, GATA-4, neuron-specific enolase, and vimentin were the most consistently expressed markers (12 of 12). Cytokeratins AE1/AE3 were also consistently expressed (11 of 12). Inhibin-α and protein gene product 9.5 were expressed in 8 and 10 sex cord-stromal tumors, respectively. Results indicate that immunoreactivity of nonhuman primate sex cord-stromal tumors is similar to that observed in other species and that calretinin, GATA-4, and neuron-specific enolase are the most consistently expressed markers in nonhuman primate sex cord-stromal tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22273575     DOI: 10.1177/0300985811432345

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  2 in total

1.  Urogenital Lesions in Nonhuman Primates at 2 National Primate Research Centers.

Authors:  Shannon Kirejczyk; Christopher Pinelli; Olga Gonzalez; Shyamesh Kumar; Edward Dick; Sanjeev Gumber
Journal:  Vet Pathol       Date:  2020-11-19       Impact factor: 2.221

Review 2.  The molecular mechanism of ovarian granulosa cell tumors.

Authors:  Jiaheng Li; Riqiang Bao; Shiwei Peng; Chunping Zhang
Journal:  J Ovarian Res       Date:  2018-02-06       Impact factor: 4.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.